IsoPlexis’ Blood-Based Biomarker Predicts Progression-Free Survival in Melanoma Study

  • On November 11th at the 2020 SITC conference, data from a clinical trial in collaboration with Nektar Therapeutics was presented, assessing the relationship between Nivo/Bempeg (NKTR-214) treatment and progression-free survival in metastatic melanoma patients.
  • IsoPlexis’ platform found that the week 1 Polyfunctional Strength Difference (PSD) of CD8+ T cells from the blood was a highly predictive biomarker of progression-free survival.
  • IsoPlexis’ functional immune landscaping is able to predict the progression-free survival at week one, when patient response typically isn’t able to be evaluated until weeks later.

Researchers Present Single-Cell Functional Proteomics Data at SITC 2020 Annual Meeting

Data utilizing IsoPlexis’ single-cell proteomics was presented at the 2020 SITC conference, on November 11th in a presentation titled, “Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study.” IsoPlexis’ functional proteomics predicted progression-free survival of metastatic melanoma patients treated with the Nivo/Bempeg (NKTR-214) combination therapy.

IsoPlexis, the gold standard in single-cell functional proteomics for precision immune medicine, first partnered with Nektar Therapeutics, the developer of NKTR-214, in June of 2018. IsoPlexis’ functional immune landscaping has been used to profile the effects of NKTR-214 in both monotherapy and combination immunotherapies in a clinical setting. In a previous study published in Nature Communications, IsoPlexis’ functional immune landscaping was used to analyze the results of adoptive cell transfer (ACT) when used in combination with Nektar’s NKTR-214 (Bempeg) rather than the traditional IL-2. In this paper, researchers showed that NKTR-214 had increased T cell polyfunctionality, proliferation, homing, and persistence, leading to improved anti-tumor function in human and murine tumors. The data from the PIVOT-02 study discussed at SITC examined T cell response to the Bempeg (NKTR-214) product when combined with Nivolumab (Nivo) immunotherapy to treat melanoma patients.

Polyfunctional Strength Difference Predicts Progression-Free Survival in Metastatic Melanoma

Using IsoPlexis’ unique technology, researchers identified a blood-based biomarker which predicted progression-free survival in melanoma patients. The researchers found that the week 1 Polyfunctional Strength Difference (PSD) of CD8+ T cells, defined by (Polyfunctional Strength Index [PSI] on Day 8) ­– (PSI on Day 1) predicted eventual response to the Nivo/Bempeg treatment in first line metastatic melanoma. Importantly, progression-free survival curves was stratified by PSD.

The predictive blood-based biomarker identified by IsoPlexis’ platform enables researchers to evaluate patient response to Nivo/Bempeg therapy much earlier than was previously possible traditional technologies. IsoPlexis’ blood-based biomarker is measured in week 1, on the eighth day of treatment, much earlier than other methods which occur several weeks later. With this finding, IsoPlexis accelerates insights into the path toward overcoming difficult-to-treat cancers such as metastatic melanomas, identifying treatments associated with a durable response in patients.

Learn more about IsoPlexis’ unique functional proteomics and newest innovations here.

Share This Article
Be in the Know.
Unlock Resources

We will always keep your personal information safe. Complete this form to get unlimited access to all of our web resources and join over 10,000 leading researchers who receive industry pioneers' backed data straight to their inbox. By submitting this form, you agree to receive communications from IsoPlexis and accept our Privacy Policy.

You may unsubscribe and update your email subscription at any time.